Katharine F. Michel

Katharine F. Michel

Auto-generated profile, based on publicly available information

Katharine F. Michel

Division of Urology, Department of Surgery, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2020 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MSMarshall C. Strother
Marshall C. Strother
KMKatharine F. Michel
Katharine F. Michel
LXLeilei Xia
Leilei Xia
KMKellie McWilliams
Kellie McWilliams
TGThomas J. Guzzo
Thomas J. Guzzo
DLDavid I. Lee
David I. Lee

3 May 2021 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
KMKatharine F. Michel
Katharine F. Michel
ASAleigha Spaulding
Aleigha Spaulding
AJAhmedin Jemal
Ahmedin Jemal
KYK. Robin Yabroff
K. Robin Yabroff
DLDaniel J. Lee
Daniel J. Lee
XHXuesong Han
Xuesong Han
One of the major components of the 2010 Patient Protection and Affordable Care Act (ACA) was the expansion of Medicaid coverage eligibility to 138% of the federal poverty level (FPL). While this expansion was intended to decrease rates of the individuals who are uninsured across the entire US population, in 2012, the Supreme Court made this expansion optional for states.1 In January 2014, 25 states and the District of Columbia opted to expand Medicaid, and several more states expanded in the ensuing years.2 This staggered and incomplete expansion pattern provides a natural experiment to study the association of the Medicaid expansion with population health.

1 September 2024 in Urology Practice
Verified
Journal Article
Closed access
KMKatharine F. Michel
Katharine F. Michel
MSMichelle Slinger
Michelle Slinger
HSHanna Stambakio
Hanna Stambakio
BSBenjamin T. Schurhamer
Benjamin T. Schurhamer
JZJustin B. Ziemba
Justin B. Ziemba


1 May 2024 in Urology Practice
Verified
Journal Article
Closed access
IHI. Mitchell Harmatz
I. Mitchell Harmatz
KAKhalid Y. Alkhatib
Khalid Y. Alkhatib
MLMorgan Leff
Morgan Leff
JNJosé Ignacio Nolazco
José Ignacio Nolazco
KMKatharine F. Michel
Katharine F. Michel
PPPhillip M. Pierorazio
Phillip M. Pierorazio
Cigarette smoking is associated with higher-risk prostate cancer at the time of diagnosis and increased overall and prostate cancer‒specific mortality. Previous studies indicate smokers are less likely to undergo PSA screening. Herein we investigate the association between smoking and PSA screening using a nationally representative US survey. We hypothesize that smokers are less likely to undergo guideline-concordant PSA screening. We performed a cross-sectional analysis of men aged 55 to 69 who responded to the cigarette smoking and PSA screening questions of the 2018 Behavioral Risk Factor Surveillance System survey. Adjusted prevalence and adjusted risk differences were calculated using complex weighted multivariable Poisson regression modeling. We identified 58,996 individuals who qualified for analysis. PSA screening prevalence was 39% (95% CI: 39%-40%) nationally, 42% (95% CI: 41%-44%) for never smokers, 42% (95% CI: 39%-40%) for former smokers, and 27% (95% CI: 25%-29%) for current smokers, including 27% (95% CI: 24%-29%) for daily smokers and 29% (95% CI: 24%-33%) for nondaily smokers. Compared to never smokers, the adjusted relative risk for undergoing PSA screening was 0.81 for current smokers (95% CI: 0.75-0.88, P < .01) and 0.99 for former smokers (95% CI: 0.94-1.03, P = .53). Current smokers are less likely to undergo recommended PSA screening, but former smokers are screened at similar rates as never smokers. As delays in diagnosis may substantially contribute to worse prostate cancer outcomes, targeted interventions to increase screening in this population may yield significant effects.

13 September 2024 in Neurourology and Urodynamics
Verified
Journal Article
Open access
KMKatharine F. Michel
Katharine F. Michel
ARAvanti N. Rangnekar
Avanti N. Rangnekar
MSMichelle Slinger
Michelle Slinger
ZGZoe S. Gan
Zoe S. Gan
ASAriana L. Smith
Ariana L. Smith
Background and Objectives: Overactive bladder and its hallmark symptom, urgency, are thought to be multifactorial in pathogenesis. Smoking is a particularly important risk factor to understand because it is modifiable; studies evaluating an association between smoking and urgency have been inconclusive. We therefore sought to rigorously assess the relationship between smoking and urgency in terms of both a temporal and quantitative pack year history of smoking while controlling for other possible confounding factors.Methods: Community‐based adult women were recruited using the ResearchMatch website to participate in an online survey of bladder health which included questions to assess urgency symptoms, medical comorbidities, and detailed smoking history. Smoking history was studied as the independent variable in three different formulations: smoking status (never vs. former vs. current), continuous pack year history, and categorical pack year history. The outcomes studied included urgency (any urgency in the past 7 days), moderate urgency (urgency at least half the time), and urgency urinary incontinence (UUI). Chi‐square tests were performed to detect associations between smoking and these outcomes, and multivariate regression was then performed to control for possible confounders and to help determine the comparative influence of temporality versus quantity of smoking history.Results: In 1720 women who completed the questionnaire, current smoking status was associated with a 23% increase in the risk of experiencing urgency (RR 1.23) and a 78% increase in the risk of experiencing moderate urgency (RR 1.78) relative to never smokers. The risk of experiencing UUI was 40% higher (RR 1.40). Lifetime pack year history was also significantly associated with urgency outcomes, although only in smokers/former smokers who had a 20+ pack year history (RR 1.15, 1.60, and 1.25 for urgency, moderate urgency, and UUI, respectively). The presence of former smoking history was not significantly associated with urgency outcomes, even when controlling for cumulative pack years.Conclusions: This analysis of a large cross‐sectional database of women suggests a strong, consistent link between current smoking status and urinary urgency and UUI. By contrast, no increased risk of urgency was attributed to former smoking status. Analysis of pack year history suggests a dose–response relationship wherein ≥ 20 pack years was significantly associated with a higher risk of all urgency outcomes. In models controlling for pack year history, the association of current smoking with urgency remained significant and former smoking remained nonsignificant. Taken together, this supports greater attention being given to the contribution of current smoking to urgency symptoms, and to the need for further longitudinal work to determine if smoking cessation can be a strategy to treat urgency.